Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo

Neuroscience Letters

Volumn 486, Issue 3, 2010, Pages 235-239

  Chinta, Shankar J ^a   Mallajosyula, Jyothi K ^a   Rane, Anand ^a   Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Alpha synuclein ( syn); Mitochondria; Mitochondrial complex I (CI) activity; Mitophagy; Oligomers; Parkinson's disease; Proteasomal inhibition

Indexed keywords

ALPHA SYNUCLEIN; FREE RADICAL; MONOMER; OLIGOMER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; DOPAMINERGIC NERVE CELL; IN VIVO STUDY; LEWY BODY; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; TRANSGENIC ANIMAL;

AGING; ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTRON TRANSPORT COMPLEX I; MICE; MICE, TRANSGENIC; MITOCHONDRIAL MEMBRANES; NEURONS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; SUBSTANTIA NIGRA;

EID: 78049383132     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.09.061     Document Type: Article

References (32)

1. Abou-Sleiman P.M., Muqit M.M., Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006, 7:207-219.
2. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 2005, 58:495-505.
3. Budd D.C., Nicholls D.G. Protein kinase C-mediated suppression of the presynaptic adenosine A1 receptor by a facilitatory metabotropic glutamate receptor. J. Neurochem. 1995, 65(2 (August)):615-621.
4. Buttner S., Bitto A., Ring J., Augsten M., Zabrocki P., Eisenberg T., Jungwirth H., Hutter S., Carmona-Gutierrez D., Kroemer G., Winderickx J., Madeo F. Functional mitochondria are required for alpha-synuclein toxicity in aging yeast. J. Biol. Chem. 2008, 283(12):7554-7560.
5. Chinta S.J., Kumar M.J., Hsu M., Rajagopalan S., Kaur D., Rane A., Nicholls D.G., Choi J., Andersen J.K. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J. Neurosci. 2007, 27(51 (December 19)):13997-14006.
6. Cole N.B., Dieuliis D., Leo P., Mitchell D.C., Nussbaum R.L. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 2008, 314(10):2076-2089.
7. Cuervo A.M., Stefanis L., Fredenburg R., Lansbury P.T., Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305:1292-1295.
8. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., Rocha M., Jackson-Lewis V., Hersch S., Sulzer D., Przedborski S., Burke R., Hen R. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14524-14529.
9. Davey G.P., Peuchen S., Clark J.B. Energy thresholds in brain mitochondria. Potential involvement in neurodegeneration. J. Biol. Chem. 1998, 273(21 (May 22)):12753-12757.
10. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 2008, 283(14):9089-9100.
11. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:3413-3418.
12. Kim I., Rodriguez-Enriquez S., Lemasters J.J. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 2007, 462(2 (June 15)):245-253.
13. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A., Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 2006, 21:541-548.
14. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 1998, 18:106-108.
15. Li W.W., Yang R., Guo J.C., Ren H.M., Zha X.L., Cheng J.S., Cai D.F. Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 2007, 18:1543-1546.
16. Liu G., Zhang C., Yin J., Li X., Cheng F., Li Y., Yang H., Uéda K., Chan P., Yu S. alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009 May 1, 454(3):187-192.
17. Loeb V., Yakunin E., Saada A., Sharon R. The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J. Biol. Chem. 2010, 285(10 (March 5)):7334-7343.
18. Mallajosyula J.K., Kaur D., Chinta S.J., Rajagopalan S., Rane A., Nicholls D.G., Di Monte D.A., Macarthur H., Andersen J.K. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS ONE 2008, 3(2):e1616.
19. McNaught K.S., Perl D.P., Brownell A.L., Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann. Neurol. 2004, 56:149-162.
20. Moore D.J., West A.B., Dawson V.L., Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 2005, 28:57-87.
21. Norris E.H., Uryu K., Leight S., Giasson B.I., Trojanowski J.Q., Lee V.M. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol. 2007, 170:658-666.
22. Orth M., Tabrizi S.J., Tomlinson C., Messmer K., Korlipara L.V., Schapira A.H., Cooper J.M. G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem. Int. 2004, 45:669-676.
23. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol. Life Sci. 2008, 65(7-8):1272-1284.
24. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
25. Richfield E.K., Thiruchelvam M.J., Cory-Slechta D.A., Wuertzer C., Gainetdinov R.R., Caron M.G., Di Monte D.A., Federoff H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 2002, 175(1 (May)):35-48.
26. Shavali S., Brown-Borg H.M., Ebadi M., Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci. Lett. 2008, 439(2):125-128.
27. Smith W.W., Jiang H., Pei Z., Tanaka Y., Morita H., Sawa A., Dawson V.L., Dawson T.M., Ross C.A. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alphasynuclein-induced toxicity. Hum. Mol. Genet. 2005, 14:3801-3811.
28. Song D.D., Shults C.W., Sisk A., Rockenstein E., Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 2004, 186:158-172.
29. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
30. Tabrizi S.J., Orth M., Wilkinson J.M., Taanman J.W., Warner T.T., Cooper J.M., Schapira A.H. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. 2000, 9:2683-2689.
31. Takeuchi H., Kondo Y., Fujiwara K., Kanzawa T., Aoki H., Mills G.B., Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 2005, 65:3336-3346.
32. Volles M.J., Lansbury P.T. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 2003, 42:7871-7878.